http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-54594-U
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_071951dd7dfb2d38df0b292f2d09957f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2010-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2b8fbb7665699b09a0f8de290c26de0 |
| publicationDate | 2010-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-54594-U |
| titleOfInvention | METHOD OF ASSESSING PHARMACOLOGICAL CORRECTION EFFECTIVENESS WITH DOCSORUBICIN CARDIOMYOPATHY |
| abstract | A method for evaluating the effectiveness of pharmacological correction under the conditions of doxorubicin cardiomyopathy involves a blood test. Against the background of doxorubicin cardiomyopathy, lipoflavone is administered intramuscularly with a dose of 5 mg / kg of weight daily for four weeks, the change in the degree of erythrocyte hemolysis is determined, the obtained results are compared with the control and, when the indicators change, the pharmacological correction of energy metabolism in the myocardium is evaluated. |
| priorityDate | 2010-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703 |
Total number of triples: 13.